Compare · CORT vs NVO
CORT vs NVO
Side-by-side comparison of Corcept Therapeutics Incorporated (CORT) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CORT and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 21.1x CORT ($10.24B).
- Over the past year, CORT is up 37.7% and NVO is down 29.3% - CORT leads by 67.0 points.
- CORT has been more active in the news (6 items in the past 4 weeks vs 4 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 15 for CORT).
- Company
- Corcept Therapeutics Incorporated
- Novo Nordisk A/S
- Price
- $95.30-1.44%
- $48.78+1.22%
- Market cap
- $10.24B
- $215.95B
- 1M return
- +16.75%
- +2.89%
- 1Y return
- +37.70%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2004
- News (4w)
- 6
- 4
- Recent ratings
- 15
- 25
Corcept Therapeutics Incorporated
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with serous ovarian tumors, as well as in Phase III clinical trial for the treatment of solid tumors. The company is also developing selective cortisol modulator combined with Xtandi that is in open label dose finding trial to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest CORT
- Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
- Director Wilson James N sold $882,986 worth of shares (10,000 units at $88.30) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Mokari Atabak exercised 40,000 shares at a strike of $21.56 and sold $3,508,277 worth of shares (40,000 units at $87.71) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Business Officer Robb Gary Charles gifted 600 shares, decreasing direct ownership by 2% to 25,081 units (SEC Form 4)
- Chief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65 and sold $1,862,530 worth of shares (20,000 units at $93.13) as part of a pre-agreed trading plan (SEC Form 4)
- Officer Maduck Sean exercised 25,000 shares at a strike of $8.27 and sold $2,208,737 worth of shares (25,000 units at $88.35) as part of a pre-agreed trading plan (SEC Form 4)
- Director Mahoney David L sold $1,690,506 worth of shares (20,000 units at $84.53) (SEC Form 4)
- Director Wilson James N sold $832,049 worth of shares (10,000 units at $83.20) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 8-K filed by Corcept Therapeutics Incorporated
- Chief Financial Officer Mokari Atabak exercised 40,000 shares at a strike of $19.26 and sold $3,245,900 worth of shares (40,000 units at $81.15) as part of a pre-agreed trading plan (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S